241 related articles for article (PubMed ID: 26063687)
1. Experience with erlotinib in the treatment of non-small cell lung cancer.
Landi L; Cappuzzo F
Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
[TBL] [Abstract][Full Text] [Related]
2.
McMahon NP; Solanki A; Wang LG; Montaño AR; Jones JA; Samkoe KS; Tichauer KM; Gibbs SL
Theranostics; 2024; 14(7):2816-2834. PubMed ID: 38773974
[No Abstract] [Full Text] [Related]
3. Advances on EGFR mutation for lung cancer.
Metro G; Crinò L
Transl Lung Cancer Res; 2012 Mar; 1(1):5-13. PubMed ID: 25806150
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
Lourdes LS; Jalal SI; Hanna N
Oncologist; 2015 Sep; 20(9):975-8. PubMed ID: 26268739
[TBL] [Abstract][Full Text] [Related]
5. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.
Voon PJ; Chul Cho B; Yeo WL; Soo RA
J Thorac Dis; 2010 Sep; 2(3):144-53. PubMed ID: 22263036
[TBL] [Abstract][Full Text] [Related]
6. Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.
Li W; Zhou F; Zhou C
Onco Targets Ther; 2014; 7():253-61. PubMed ID: 24611018
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of non-small cell lung cancer brain metastases.
Cedrych I; Kruczała MA; Walasek T; Jakubowicz J; Blecharz P; Reinfuss M
Contemp Oncol (Pozn); 2016; 20(5):352-357. PubMed ID: 28373815
[TBL] [Abstract][Full Text] [Related]
8. Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Ganjoo KN; Wakelee H
Biologics; 2007 Dec; 1(4):335-46. PubMed ID: 19707304
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced non small cell lung cancer.
Bareschino MA; Schettino C; Rossi A; Maione P; Sacco PC; Zeppa R; Gridelli C
J Thorac Dis; 2011 Jun; 3(2):122-33. PubMed ID: 22263075
[TBL] [Abstract][Full Text] [Related]
10. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials.
Mangla B; Mittal P; Kumar P; Aggarwal G
Med Oncol; 2024 Jun; 41(7):173. PubMed ID: 38864966
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer.
Nurwidya F; Murakami A; Takahashi F; Takahashi K
Cancer Biol Med; 2012 Mar; 9(1):18-22. PubMed ID: 23691449
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib resistance in lung cancer: current progress and future perspectives.
Tang J; Salama R; Gadgeel SM; Sarkar FH; Ahmad A
Front Pharmacol; 2013; 4():15. PubMed ID: 23407898
[TBL] [Abstract][Full Text] [Related]
13. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review.
Ellis PM; Coakley N; Feld R; Kuruvilla S; Ung YC
Curr Oncol; 2015 Jun; 22(3):e183-215. PubMed ID: 26089730
[TBL] [Abstract][Full Text] [Related]
14. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WE; Fischer JR; von der Schulenburg JM; Mezger J; Schumann C; Serke M; Zaun S; Dietel M; Thomas M
Cancer Epidemiol Biomarkers Prev; 2015 Aug; 24(8):1254-61. PubMed ID: 26070531
[TBL] [Abstract][Full Text] [Related]
16. An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre.
Ma K; Cohen V; Kasymjanova G; Small D; Novac K; Peterson J; Levit A; Agulnik J
Curr Oncol; 2015 Jun; 22(3):e157-63. PubMed ID: 26089726
[TBL] [Abstract][Full Text] [Related]
17. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.
Ning J; Wu Q; Liu Z; Wang J; Lin X
J Recept Signal Transduct Res; 2016; 36(1):37-44. PubMed ID: 26096169
[TBL] [Abstract][Full Text] [Related]
18. EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models.
Laurila N; Koivunen JP
Med Oncol; 2015 Jul; 32(7):205. PubMed ID: 26081015
[TBL] [Abstract][Full Text] [Related]
19. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
